CN1857441A - Preparation and application of total salvianolic acid composition - Google Patents
Preparation and application of total salvianolic acid composition Download PDFInfo
- Publication number
- CN1857441A CN1857441A CN 200610046078 CN200610046078A CN1857441A CN 1857441 A CN1857441 A CN 1857441A CN 200610046078 CN200610046078 CN 200610046078 CN 200610046078 A CN200610046078 A CN 200610046078A CN 1857441 A CN1857441 A CN 1857441A
- Authority
- CN
- China
- Prior art keywords
- total
- content
- salvianolic acid
- flavone
- flavones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 title claims abstract description 60
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 title claims abstract description 60
- 229930183842 salvianolic acid Natural products 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 45
- 235000011949 flavones Nutrition 0.000 claims abstract description 70
- 229930003944 flavone Natural products 0.000 claims abstract description 67
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 21
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 21
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 150000007965 phenolic acids Chemical class 0.000 claims abstract description 16
- 229930182490 saponin Natural products 0.000 claims abstract description 11
- 150000007949 saponins Chemical class 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 5
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract 2
- 150000002213 flavones Chemical class 0.000 claims description 46
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 claims description 18
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 18
- IBGBGRVKPALMCQ-UHFFFAOYSA-N 3,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1O IBGBGRVKPALMCQ-UHFFFAOYSA-N 0.000 claims description 18
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 claims description 18
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 18
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 18
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 18
- 235000003935 Hippophae Nutrition 0.000 claims description 17
- 241000229143 Hippophae Species 0.000 claims description 17
- 241000218628 Ginkgo Species 0.000 claims description 16
- 235000011201 Ginkgo Nutrition 0.000 claims description 16
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 16
- 229930182470 glycoside Natural products 0.000 claims description 14
- 150000002338 glycosides Chemical class 0.000 claims description 14
- 235000009048 phenolic acids Nutrition 0.000 claims description 14
- 241000628997 Flos Species 0.000 claims description 13
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 13
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 11
- -1 phenolic acid compounds Chemical class 0.000 claims description 10
- 235000017709 saponins Nutrition 0.000 claims description 10
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims description 9
- 206010008118 cerebral infarction Diseases 0.000 claims description 9
- 229960003371 protocatechualdehyde Drugs 0.000 claims description 9
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims description 9
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 claims description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 229930182478 glucoside Natural products 0.000 claims description 3
- 150000008131 glucosides Chemical class 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 3
- 238000010521 absorption reaction Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 abstract description 4
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 3
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 abstract 5
- 230000002490 cerebral effect Effects 0.000 abstract 2
- 208000019553 vascular disease Diseases 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000132521 Erigeron Species 0.000 abstract 1
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 241001412304 Ixeris Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 57
- 239000000843 powder Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000002775 capsule Substances 0.000 description 32
- 239000008215 water for injection Substances 0.000 description 16
- 239000011347 resin Substances 0.000 description 11
- 229920005989 resin Polymers 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000945 filler Substances 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 238000005303 weighing Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 239000003463 adsorbent Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000000582 semen Anatomy 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241001092040 Crataegus Species 0.000 description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 4
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 4
- 235000009685 Crataegus X maligna Nutrition 0.000 description 4
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 4
- 235000009486 Crataegus bullatus Nutrition 0.000 description 4
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 4
- 235000009682 Crataegus limnophila Nutrition 0.000 description 4
- 235000004423 Crataegus monogyna Nutrition 0.000 description 4
- 235000002313 Crataegus paludosa Nutrition 0.000 description 4
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 206010069729 Collateral circulation Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to compound preparation with total salvianolic acid composition as main component for treating cardiac and cerebral vascular diseases. The total salvianolic acid composition contains total salvianolic acid in 1-99 wt%, and total haw stem and leaf phenolic acid, gingko leaf flavonid, sowthistle-leaf ixeris flavonid, safflower flavonid, total astragalus flavone and saponin, general peony glycosideor, seabuckthorn flavonid, pueraria flavonid, or total erigeron braviscapus flavone in 1-99 wt%, and is compounded with pharmaceutically acceptable supplementary material to prepare pharmaceutically acceptable preparations. The medicine of the present invention is used in preventing and treating cardiac and cerebral vascular diseases, senile dementia, and other diseases.
Description
Technical field:
The present invention relates to a kind of compound preparation of the treatment cardiovascular and cerebrovascular disease based on total salvianolic acid composition.And the application of various preparations in pharmaceutical field that utilizes the inventive method to obtain, the particularly application in the medicine of preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and other various diseases of causing by cerebral ischemia thereof etc.Make a distinction between the important and the lesser one in the full side of medicine of the present invention, compatibility is proper, and complementation is short mutually.
Background technology:
Radix Salviae Miltiorrhizae, Fructus Crataegi, Semen Ginkgo, Herba Ixeritis Sonchifoliae, Flos Carthami, the Radix Astragali, Radix Paeoniae Rubra, the Radix Paeoniae Alba, Fructus Hippophae, Herba Erigerontis etc. all are China's conventional Chinese medicines, its medicine as the treatment cardiovascular and cerebrovascular disease has basis of clinical application widely and long clinical application history, and evident in efficacy.Modern pharmacology studies show that effects such as salvianolic acid has the myocardium shrinkage function of improvement, blood vessel dilating, brings high blood pressure down, improves coronary artery and cerebral artery blood flow amount, anticoagulant, raising cell hypoxia-bearing capability; Total phenolic acids of Caulis Crataegi and Folium Crataegi improves significantly to the blood ability of penetrating, the oxygen metabolism effect tool of heart, can significantly increase cardiac output and cardiac output, increases venous oxygen content, reduces myocardial oxygen consumption, improves the blood supply oxygen supply of cardiac muscle; Folium Ginkgo total flavones and Herba Ixeritis Sonchifoliae total flavones have effects such as blood vessel dilating, blood flow increasing, blood viscosity lowering, quickening blood flow rate, anti-hypoxia; Flos Carthami total flavone has effects such as coronary artery dilator, coronary blood flow increasing, microcirculation improvement, blood fat reducing, blood pressure lowering; Radix Astragali total flavones and total saponins thereof have the myocardium shrinkage function of improvement, dwindle myocardial infarction area, alleviate myocardial damage, improve myocardial ischemia, protect effects such as cardiovascular and cerebrovascular vessel, microcirculation improvement, antiviral property myocarditis; Peoniflorin have promote learning memory disorder due to learning and memory, the antagonism scopolamine, significantly improve learning memory disorder due to the cerebral ischemia re-pouring, improve effects such as body microcirculating state, blood viscosity lowering, the inductive platelet aggregation of inhibition ADP; Breviscapine can reduce Peripheral resistance, reduce myocardial oxygen consumption, promote collateral circulation, anticoagulant, improve cardiovascular and cerebrovascular circulation, increase effects such as cardiovascular and cerebrovascular vessel blood flow.Modern clinical research shows that Fructus Hippophae total flavones has curative effect preferably for angina pectoris, coronary heart disease.
How to overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of treatment diseases of cardiovascular and cerebrovascular systems, making it to bring into play the best use of at aspect such as improve cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging, improve the quality of living is its maximum difficult point.
Summary of the invention:
The objective of the invention is defective and deficiency at above-mentioned prior art existence, provide a kind of and can overcome the shortcoming of taking single medicinal material, reasonable compatibility, short complementary mutually, make it to become effective good recipe of treatment diseases of cardiovascular and cerebrovascular systems, make it that the best use of is brought into play in the aspect improving cardio-cerebrovascular function and control aging of brain, raise immunity, slow down aging, improve the quality of living etc.
Further aim of the present invention provides the salvianolic acid compositions (compositions of salvianolic acid and total phenolic acids of Caulis Crataegi and Folium Crataegi, the compositions of salvianolic acid and Folium Ginkgo total flavones, the compositions of salvianolic acid and Herba Ixeritis Sonchifoliae total flavones, salvianolic acid and total safflower flavone composition, salvianolic acid and Radix Astragali total flavones and total astragalin composition, the compositions of salvianolic acid and Radix Paeoniae Alba total glycosides, the compositions of salvianolic acid and Fructus Hippophae total flavones, Radix Salviae Miltiorrhizae total phenolic acids and breviscapine compositions) and the application of preparation in pharmaceutical field, particularly be used to prevent and treat cardiovascular and cerebrovascular disease in preparation, senile dementia, other dysfunction that cerebral ischemia causes, the medicine of the anti-ageing disease of waiting for a long time.
The present invention is implemented by following technical proposals.
The present invention relates to a kind of is the method for the compound preparation of main preparation control cardiovascular and cerebrovascular disease, senile dementia, cerebral ischemia and other various diseases of being caused by cerebral ischemia thereof etc. by the salvianolic acid compositions, it is characterized in that this method comprises following content:
(1) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) 99～1 parts of 1～99 part and total phenolic acids of Caulis Crataegi and Folium Crataegi (content of total phenolic acid is 20%～100% in the total phenolic acids of Caulis Crataegi and Folium Crataegi), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(2) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) 99～1 parts of 1～99 part and Folium Ginkgo total flavoness (content of total flavone is 20%～100% in the Folium Ginkgo total flavones), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(3) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) 99～1 parts of 1～99 part and Herba Ixeritis Sonchifoliae total flavoness (content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(4) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) 99～1 parts of 1～99 part of and Flos Carthami total flavones (content of total flavone is 20%～100% in the total flavones), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(5) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) (content of total flavone is 30%～90% in the Radix Astragali total flavones for 1～99 part and Radix Astragali total flavones and total saponins, the content of total saponins is 10%～90%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(6) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) 1～99 part and Radix Paeoniae Alba total glycosides (comprise Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides, wherein the content of Radix Paeoniae Alba total glycosides is 20%～100%) 99～1 parts, respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(7) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) 99～1 parts of 1～99 part and Fructus Hippophae total flavoness (content of total flavone is 20%～100% in the Fructus Hippophae total flavones), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
(8) (total content of compositions such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and the total content of danshensu and salvianolic acid B is 20%～98% to get salvianolic acid respectively according to composition by weight calculating.) 99～1 parts of 1～99 part and breviscapines (content of flavone is 50%～100% in the breviscapine), respectively or mix the back and add suitable adjuvant such as antioxidant, chelating agent, filler, framework material etc. and make said various preparations on any pharmaceutics.As be used for can be made into forms such as corresponding tablet, granule, capsule when oral; Make powder pin, freeze-dried powder, transfusion etc. when being used to inject.
The specific embodiment
The following examples can help those skilled in the art more fully to understand the present invention.But do not limit the present invention in any way.
Embodiment 1 salvianolic acid Fructus Crataegi freeze-dried powder
Get salvianolic acid 2g respectively, total phenolic acids of Caulis Crataegi and Folium Crataegi 0.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 2 salvianolic acid Folium Ginkgo lyophilized powder pins
Get salvianolic acid 1.5g respectively, Folium Ginkgo total flavones 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 3 salvianolic acid Ixers sonchifolia freeze-dried powders
Get salvianolic acid 2g respectively, Herba Ixeritis Sonchifoliae total flavones 1.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 4 salvianolic acid Radix Paeoniae freeze-dried powders
Get salvianolic acid 1g respectively, Radix Paeoniae Alba total glycosides 2.5g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 5 salvianolic acid Flos Carthami freeze-dried powders
Get salvianolic acid 2.5g respectively, Flos Carthami total flavone 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 6 salvianolic acid Radix Astragali freeze-dried powders
Get salvianolic acid 2.5g respectively, Radix Astragali total flavones and total saponins 1.0g mix the back with an amount of water for injection dissolving, add 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 7 salvianolic acid Fructus Hippophae freeze-dried powders
Get salvianolic acid 2g respectively, Fructus Hippophae total flavones 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 8 salvianolic acid breviscapine frozen dry powders
Get salvianolic acid 2.5g respectively, breviscapine Fructus Hippophae total flavones 1.0g mixes the back with an amount of water for injection dissolving, adds 16g mannitol, after the dissolving, be diluted to 200ml, filter with water for injection, fill, lyophilizing adopts conventional injectable powder preparation method can obtain 100 freeze-dried powders.
Embodiment 9 salvianolic acid Folium Ginkgo capsule
Get salvianolic acid 20g respectively, Folium Ginkgo total flavones 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 10 salvianolic acid Fructus Crataegi capsules
Get salvianolic acid 15g respectively, total phenolic acids of Caulis Crataegi and Folium Crataegi 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 11 salvianolic acid Herba Ixeritis Sonchifoliae capsules
Get salvianolic acid 15g respectively, Herba Ixeritis Sonchifoliae total flavones 20g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 12 salvianolic acid Radix Paeoniae capsules
Get salvianolic acid 20g respectively, Radix Paeoniae Alba total glycosides 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 13 salvianolic acid safflower capsules
Get salvianolic acid 15g respectively, Flos Carthami total flavone 8g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 14 salvianolic acid Radix Astragali capsules
Get salvianolic acid 10g respectively, Radix Astragali total flavones and total saponins 20g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 15 salvianolic acid Fructus Hippophae capsules
Get salvianolic acid 20g respectively, Fructus Hippophae total flavones 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
Embodiment 16 salvianolic acid breviscapine capsules
Get salvianolic acid 25g respectively, breviscapine 15g, starch 150g adopts conventional capsule preparation method thereof can make 1000 capsules after mixing.
The extraction of embodiment 17 Herba Erigerontis total flavones, total phenolic acids of Caulis Crataegi and Folium Crataegi, Folium Ginkgo total flavones, Herba Ixeritis Sonchifoliae total flavones, Flos Carthami total flavone, Radix Puerariae total flavones, Fructus Hippophae total flavones, Radix Astragali total flavones
(1) takes by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Fructus Hippophae or Radix Astragali 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, add 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, etc., hyposynchronization also can save), extractions such as ethyl acetate or n-butyl alcohol or n-amyl alcohol, get final product behind the recovery organic solvent the total flavones crude product.
(2) take by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Fructus Hippophae or Radix Astragali 1Kg, add 6～10 times of water gagings, regulate pH to 8～9, decocted 0.5～3 hour, filter, extract so repeatedly 1～3 time with lime cream.Merge extractive liquid, is chilled to below 70 ℃, regulates pH to 3～5 with acid (comprising mineral acid and organic acid such as acetic acid, trichloroacetic acid such as hydrochloric acid, sulphuric acid), and is static, filter get final product the total flavones crude product.
(3) take by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Fructus Hippophae or Radix Astragali 1Kg, water or different concentration ethanol are extracted 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol or methanol-eluted fractions successively, collect different concentration ethanol or methanol-eluted fractions fraction, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
(4) take by weighing Herba Erigerontis or hawthorn stem and leaf or Semen Ginkgo stem and leaf or Herba Ixeritis Sonchifoliae or Flos Carthami or Fructus Hippophae or Radix Astragali 1Kg, water or different concentration ethanol are extracted 1～3 time, and (the solvent consumption is 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filter, reclaim ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), separate through the polyamide chromatographic column, water, different concentration ethanol or methanol-eluted fractions are collected different concentration ethanol or methanol-eluted fractions fraction successively, reclaim get final product behind the solvent the different total flavones elaboration of purity.The total flavones crude product that obtains in above-mentioned (1 and 2) also can be by polyamide chromatographic column refining (method be the same).
The extraction of embodiment 18 Radix Paeoniae Alba total glycosides
(1) take by weighing Radix Paeoniae 1Kg, water or variable concentrations alcohol (comprising ethanol, methanol etc.) extract 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.Concentrate with suitable quantity of water dissolving (100～1000ml), with organic solvent degreasing (comprise petroleum ether, chloroform, ethyl acetate etc., hyposynchronization also can save), n-butanol extraction (comprising n-amyl alcohol etc.), reclaim get final product behind the n-butyl alcohol total glycosides slightly.
(2) take by weighing Radix Paeoniae 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol to there not being the alcohol flavor.With suitable quantity of water dissolving (100～1000ml), (comprise polarity, middle polarity and nonpolar macroporous adsorption resin through the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol eluting successively, collect the different concentration ethanol eluting fraction, get final product the different total glycosides elaboration of purity.The thick total saponins that obtains in above-mentioned (1) also can be by macroporous adsorbent resin chromatography post refining (method be the same).
The extraction of embodiment 19 Radix Salviae Miltiorrhizae total phenolic acidss
Take by weighing Radix Salviae Miltiorrhizae 1Kg, water or different concentration ethanol are extracted 1～3 time (the solvent consumption are 15Kg～30Kg), be evaporated to 0.5～1L, adds 1～4L ethanol, filters, and reclaims ethanol and can not get the salvianolic acid crude product to there being pure flavor.The salvianolic acid crude product is soluble in water, (comprise polarity, middle polarity and nonpolar macroporous adsorption resin with the separation of macroporous adsorbent resin chromatography post, the ratio of the consumption of resin and crude drug is 1: 0.2～5), water, different concentration ethanol eluting successively, collect different eluting fractions, can get the different salvianolic acid of purity.
Claims (9)
1, a kind of total salvianolic acid composition, it is characterized in that being grouped into (percentage by weight): Radix Salviae Miltiorrhizae total phenolic acids 1%～99%, total phenolic acids of Caulis Crataegi and Folium Crataegi 99%～1% or Folium Ginkgo total flavones 99%～1% or Herba Ixeritis Sonchifoliae total flavones and saponin 99%～1% or Flos Carthami total flavone 99%～1% or Radix Astragali total flavones and total saponins 99%～1% or Radix Paeoniae Alba total glycosides (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) 99%～1% or Fructus Hippophae total flavones 99%～1% or Herba Erigerontis total flavones (comprising the pure product of breviscapine) 99%～1% by following one-tenth.More particularly, be meant in Radix Salviae Miltiorrhizae total phenolic acids and the said medicine combination of any one or two or more medicines, be equipped with proper pharmaceutical excipients and make the pharmaceutically various preparations of acceptable.
2, according to right 1 described preparation, it is characterized in that: Radix Salviae Miltiorrhizae total phenolic acids is the water-soluble phenolic acid compounds in the Radix Salviae Miltiorrhizae in the described composition, the content of total composition such as its total phenolic acid compound such as danshensu, protocatechualdehyde, salvianolic acid B is 30%～100%, and wherein the content sum of danshensu and salvianolic acid B is 20%～98%.
3, according to right 1 described preparation, it is characterized in that: the content of total phenolic acid is 20%～100% in the total phenolic acids of Caulis Crataegi and Folium Crataegi in the described composition; Content of total flavone is 20%～100% in the Folium Ginkgo total flavones; Content of total flavone is 20%～100% in the Herba Ixeritis Sonchifoliae total flavones; Content of total flavone is 20%～100% in the Flos Carthami total flavone; Content of total flavone is 20%～100% in the Fructus Hippophae total flavones.
4, according to right 1 described preparation, it is characterized in that: content of total flavone is 30%～90% in Radix Astragali total flavones in the described composition and the total saponins, and the content of total saponins is 10%～90%.
5, according to right 1 described preparation, it is characterized in that: the content of the Radix Paeoniae Alba total glycosides in the Radix Paeoniae Alba total glycosides in the described composition (comprising Radix Paeoniae Rubra total glycosides and Radix Paeoniae Alba total glucosides) is 20%～100%.
6, according to right 1 described preparation, it is characterized in that: the content of flavone is 50%～100% in the Herba Erigerontis total flavones in the described composition, comprises that also content reaches the breviscapine more than 90%.
7, according to right 1 described preparation of compositions method, it is characterized in that: it is the characteristics according to various compositionss, and the modern preparation technique that allows on the employing pharmaceutics is realized.
8, all kinds of preparations of making according to right 1 described compositions, it is characterized in that: it comprises injection type, peroral dosage form, percutaneous dosing dosage form, mucosa absorption dosage form.
9, all kinds of preparations of making according to right 1 described compositions is characterized in that: be mainly used in other dysfunction, the anti-ageing disease of waiting for a long time that control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia cause.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046078 CN1857441A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of total salvianolic acid composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610046078 CN1857441A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of total salvianolic acid composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1857441A true CN1857441A (en) | 2006-11-08 |
Family
ID=37296429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610046078 Pending CN1857441A (en) | 2006-03-17 | 2006-03-17 | Preparation and application of total salvianolic acid composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1857441A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288705B (en) * | 2007-04-18 | 2010-12-22 | 北京本草天源药物研究院 | Medicine composition mainly for adjusting blood fat and its preparation method |
| CN103070943A (en) * | 2013-01-28 | 2013-05-01 | 西北农林科技大学 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
| CN103099896A (en) * | 2013-01-06 | 2013-05-15 | 车艳艳 | Herb tea for treating cardiovascular and cerebrovascular diseases |
| CN108310254A (en) * | 2018-05-04 | 2018-07-24 | 青岛大学附属医院 | A kind of preparation method of cardiovascular health natural plant composition |
| CN108452201A (en) * | 2018-05-04 | 2018-08-28 | 青岛大学附属医院 | A kind of cardiovascular health natural plant composition |
-
2006
- 2006-03-17 CN CN 200610046078 patent/CN1857441A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101288705B (en) * | 2007-04-18 | 2010-12-22 | 北京本草天源药物研究院 | Medicine composition mainly for adjusting blood fat and its preparation method |
| CN103099896A (en) * | 2013-01-06 | 2013-05-15 | 车艳艳 | Herb tea for treating cardiovascular and cerebrovascular diseases |
| CN103099896B (en) * | 2013-01-06 | 2014-10-01 | 车艳艳 | Herb tea for treating cardiovascular and cerebrovascular diseases |
| CN103070943A (en) * | 2013-01-28 | 2013-05-01 | 西北农林科技大学 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
| CN103070943B (en) * | 2013-01-28 | 2015-05-13 | 西北农林科技大学 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular diseases and preparation method of traditional Chinese medicine |
| CN108310254A (en) * | 2018-05-04 | 2018-07-24 | 青岛大学附属医院 | A kind of preparation method of cardiovascular health natural plant composition |
| CN108452201A (en) * | 2018-05-04 | 2018-08-28 | 青岛大学附属医院 | A kind of cardiovascular health natural plant composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1857473A (en) | Gynostemma pentaphylla saponin composition preparation and its preparing process | |
| CN101073599A (en) | Total tanshinone and total phenolic acid extract in red-rooted salvia root and its production | |
| CN1857388A (en) | Preparation and application of notoginseng stem and leaf total saponin composition | |
| CN1857472A (en) | Ginsenoside composition preparation and its preparing process | |
| CN1857441A (en) | Preparation and application of total salvianolic acid composition | |
| CN101700289B (en) | Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments | |
| CN100534508C (en) | Method for extracting effective sites group of smilax China root | |
| CN1229324C (en) | Extraction process of tanshin general phenolic acid and its prepn and use | |
| CN1857442A (en) | Preparation and application of ligustrazine and its salt composition | |
| CN1857377A (en) | Preparation and application of total safflower flavone composition | |
| CN100345558C (en) | Extract product of general flavone of kudzuvine root, preparation method and application | |
| CN101036708A (en) | Medicine composition for treatment of cardio-cerebralvascular disease | |
| CN1857395A (en) | Compound Chinese medicine composition for treating cardiac and cerebral vascular diseases | |
| CN1857469A (en) | Arasaponin composition preparation and its preparing process | |
| CN1857471A (en) | Tribuloside composition preparing and its preparing process | |
| CN1857439A (en) | Preparation and application of ginkgo leaf flavonid composition | |
| CN101658542B (en) | Soft-lithospermum total phenolic acid and use thereof in pharmacy | |
| CN1814149A (en) | Medicine composition for treating diabetes or diabetes kidney-disease, and preparing method | |
| CN1857470A (en) | Preparation and application of shortscape fleabane herb flavonid composition | |
| CN1857468A (en) | Prepn and application of haw heaf total phenolic acid composition | |
| CN1579485B (en) | Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof | |
| CN1857387A (en) | Preparation and application of pueraria flavonid composition | |
| CN1857443A (en) | Preparation and application of astragalus flavonid and total astragalin composition | |
| CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
| CN1686200A (en) | Tulip poplar extract, refined extract and its application in medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |